The HR-positive/HER2-negative treatment landscape is rapidly evolving with the introduction of novel antibody-drug conjugate (ADC) therapies for patients who have developed resistance to endocrine-based therapy. This shifting paradigm effectuates uncertainty for health care practitioners regarding ADC mechanisms of action (MoAs), efficacy, safety, and value to patients. The first episode of this CEC BriefCase series introduces a patient case that demonstrates real-world challenges faced by oncologists and their teams, provides insights into the latest developments in this therapeutic space, and discusses how to consider swiftly developing data as a key component of personalized treatment plans.
- Provider:Creative Educational Concepts, Inc.
- Activity Link: https://www.ceconcepts.com/activity/adcs-in-hr-her2-mbc-clinical-trial-and-real-world-data/
- Start Date: 2024-07-29 05:00:00
- End Date: 2024-07-29 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Gilead Sciences, Inc. - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Medical Oncology
Subscribe
Login
0 Comments
Oldest